Diabetic Retinopathy Study. DR was identified in 15 subjects (0.33 %) of the entire cohort. In subjects with diabetes, DR was present in 9.6 % [5] . Risk factors were increasing age and higher glucose concentrations. All eyes showed only nonsevere forms of DR. There was no significant association with other conventional risk factors or with ocular parameters. In the SN-DREAMS III report no 2 (Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study III), population-based cross-sectional screening was carried out in a rural population of south India (n, 13,079) [6] . DR was identified using 45°four-field stereoscopic digital photography, along with 30°seven-field stereo digital pairs in those with DR. Among those with diabetes, DR was identified in 10.3 %, with greater risk in men, insulin users, those with longer duration of diabetes, systolic hypertension and poor glycemic control [6] .
In urban Chennai, the CURES Eye Study I, a populationbased screening for diabetes, was carried out in adults aged 20 years and above (n, 26,001). Among 1382 known subjects with diabetes who agreed to undergo four-field stereo colour photography, and 354 newly diagnosed subjects with diabetes, DR was present in 17.6 % [7] . The prevalence of DR was higher in men and those with proteinuria.
Another population-based study in South Kerala assessed the prevalence of diabetes and DR in a community-based screening programme. One hundred and sixty camps were held in five southern districts of Kerala (Project Trinetra) [8] .
In a pilot hospital-based screening for DR from western India (n, 168) using ETDRS classification, prevalence of DR was 33.9 %; non-proliferative DR was 25.5 % and proliferative DR 8.33 % [9] .
The current issue of the Journal reports on the risk factors for DR in sub-Saharan Africa, prevalence in a rural south Indian population, and on biomarkers for DR and screening methods.
Photography of the retinal vessels has progressed from analog [10] to digital. Despite the convenience of non-mydriatic camera to screen for DR, multiple field stereo photography is necessary for precise classification. Genetic and epigenetic factors were linked to the development of DR. Microvascular dysfunction results from involvement of breakdown of blood retinal barrier, capillary basement thickening involving different cellular components of the retina including the retinal neuronal and glial dysfunction. Pathogenic pathways include altered retinal blood flow, inflammatory pathways and growth factors such as vascular endothelial growth factor (VEGF) [11] ; the latter forms the target for treatment of DR by the use of drug modulators.
Diabetic nephropathy (DN) is the other major diabetic microvascular complication accounting for significant morbidity and mortality. Metabolic and genetic factors contribute to its pathogenesis. This issue carries reports on DN relating to risk factors, early recognition, biomarkers and intervention. At the outset, one should bear in mind that non-diabetic renal disease could contribute to renal failure in diabetes mellitus. Clinical situation simplying non-diabetic renal disease includes shorter duration of diabetes, microscopic hematuria and active urinary sediment in the absence of retinopathy [12] . An Indian study showed a poor correlation between DN and DR in type 2 diabetes mellitus and suggested that renal biopsy is useful in staging the lesions in subjects with diabetes having renal dysfunction [13] . A similar discordance between DR and DN in type 2 diabetes was reported, advocating the requirement of renal biopsy for a precise renal pathological diagnosis in these situations [14] .
A number of biomarkers were studied to identify early stages of renal involvement in diabetes, which may pre-date the clinical diagnosis of diabetes. Markers of tubular damage such as urine neutrophil gelatinase-associated lipocalin and cystan C are potential biomarkers [15] . Other putative biomarkers include serum prolidase activity, which is associated with oxidative stress, also contributing to diabetic nephropathy; oxidant stress is reported as total oxidant stress, total antioxidative status and oxidative stress index [16] . Newer biomarkers employing proteomics and emerging omics technologies are likely to improve the capability to identify nephropathy at an early stage and allow aggressive interventions to prevent further progress [17] . Whereas urinary miRNAs could serve as biomarkers in diabetic complications, a recent study reported that among five detectable TGF-β1-regulated miRNAs, only circulating levels of let-7b-5p and miR-21-5p were associated with risk of end-stage renal disease [18] . However, one must bear in mind that circulating miRNA level may not correlate with tissue levels [19] .
Much focus has been directed towards the role of genetic factors contributing to DR, in view of the availability of sequencing techniques. It helps in serving as biomarkers, and in providing information into pathogenesis, and opening up avenues for new drug targets. Studies targeted gene variants of inflammatory cytokine genes (interleukins, tumour necrosis factor), extracellular matrix components (collagen, laminins, matrix metalloproteinase 9), renal function (angiotensinogen and angiotensin II receptors), endothelial function and oxidative stress (nitric oxide synthase 3, catalase, superoxide dismutase 2), and glucose and lipid metabolism (adiponectin, Apolipoprotein E, aldose reductase, glucose transporter 1, peroxisome proliferator-activated receptor gamma 2) [20] .
There have been a number of Indian studies on candidategene approach to DR. Vascular endothelial growth factor (VEGF), a potent cytokine, has a role in the pathogenesis of diabetic microvascular disease, including DN. A pilot crosssectional study (n, 40) from a North Indian population showed that DD genotype and D allele in I/D polymorphism at -2549 position of VEGF gene increased the susceptibility to DN [21] . Polymorphisms of osteopontin promoter were reported to be a genetic risk factor for DN. In a case-control study, three functional promoter gene polymorphisms and their haplotypes were studied in relation to risk of DN (C-443T, delG-156G, G-66T) [22] . The results suggested an association between the gene promoter polymorphisms and their haplotypes with risk of DN in subjects with T2DM. Transcription factor 7-like 2 (TCF7L2) gene is associated with DN. In a south Indian population, polymorphisms of the gene were studied in relation to DN [23] . The rs12255372 polymorphism in the TCF7L2 gene is associated with DN but operates through diabetes mellitus.
A larger sample from Punjab and from Jammu and Kashmir (n, 1313) was genotyped for TGF-β1 (rs1800470 and rs1800469). The CC genotype of rs1800470 increased the risk of end-stage renal disease by 3.1-4.5-fold [24] . TNF promoter polymorphism, associated with chronic low-grade inflammation, was studied in relation to susceptibility to DN. It was shown that 863C/A polymorphism might be protective against DN whereas -1031T/C may increase the risk of DN [25] .
Data on ACE2 is available from different areas of India. Angiotensin 1 receptor and angiotensin 2 receptors regulate NF-kB and ACE2, and provide a potential for identifying drug targets [26] . ACE (I/D) gene polymorphisms were reported to predispose to DN from Kutch region in western India. About 150 each of Ahir and Rabri ethnic groups with diabetes of more than 10 years were studied. Variant at ACE locus as D/D variant in intron 16 contributed to increased risk but not severity of DN [27] . Genes involved in oxidative stress pathway appear to predispose to DN [28, 29] . Replication studies for TGF β1 gene and for SNPs in RAGE and GFPT2 in India were obtained [30, 31] .
Eventually, most people with end-stage diabetic renal disease require long-term dialysis or renal transplant. While the technology for the latter is available, lack of adequate donors is a bottleneck. Monitoring the renal status for early signs of rejection is an important aspect in the post-transplant stage.
Methods for non-invasive detection of renal allograft inflammation by measuring mRNA for IP-10 and CXCR3 in urine were shown to be a potential biomarker of acute rejection [32] .
Current approach to managing DR is limited to the later stages of the condition and does not address the early stages where reversing the change can be considered. Anti-VEGF treatment is an advance, but other mechanisms can be targeted involving the retinal involvement of glia, neurons and vessels [11] . Emerging treatments in the pipeline include modifying expression of antioxidant genes, the kallekrein inhibitors and NOX-2 inhibitors. Stem cell reparative processes are also being studied in the treatment of DR [11] .
Approach to DN is also multifactorial, controlling glucose levels, blood pressure lipids and protein intake in the diet. Further understanding of the pathogenic mechanisms shows promise of newer drug targets against pathways upregulated by elevated glucose levels as well as others leading to progression of DN [33] . Recent GWAS investigations show promise of identifying novel loci influencing albuminuria in diabetes [34] .
The mix of articles in this issue reflects the trend for greater focus of genetic studies in DN compared to DR.
